Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Menagen
Muscat, Omanmenagentx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Menagen manufactures and commercializes innovative and biosimilar therapies for rare diseases, nephrology, hematology, and cardiovascular disease. Products such as biosimilar darbepoetin alfa for anemia and agalsidase beta for Fabry disease are approved or being commercialized in the Middle East and North Africa[3][4].
- Therapeutic areas
- NephrologyCardiovascularMetabolic DisordersRare Diseases
- Modalities
- Small moleculeBiologicBiosimilarEnzyme replacement therapy
- Industry
- Biotech
02
Partnerships
Chong Kun Dang Pharmaceutical Corp.JCR Pharmaceuticals
Beyond the preview
Go deeper on Menagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Menagen.